CalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

Primary objective of the trial met with statistically significant dose response with up to 43.6% relative reduction (2.1 day improvement) in median time to solid food tolerance versus placebo in hyper-inflamed patients Statistically significant dose response with up to 61.7% reduction in severe organ failure in all patients versus placebo Up to 100% reduction in hospital stays longer than 21 daysPlanning End-of-Phase 2 meeting with the FDA in preparation for a pivotal trialConference call to discuss the CAR ...